TY - JOUR T1 - Cost-effectiveness analysis of an 18-week exercise programme for patients with breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT study JF - BMJ Open JO - BMJ Open DO - 10.1136/bmjopen-2016-012187 VL - 7 IS - 3 SP - e012187 AU - Anne M May AU - Marcel J C Bosch AU - Miranda J Velthuis AU - Elsken van der Wall AU - Charlotte N Steins Bisschop AU - Maartje Los AU - Frans Erdkamp AU - Haiko J Bloemendal AU - Marnix A J de Roos AU - Marlies Verhaar AU - Daan ten Bokkel Huinink AU - Petra H M Peeters AU - G Ardine de Wit Y1 - 2017/03/01 UR - http://bmjopen.bmj.com/content/7/3/e012187.abstract N2 - Objective Meta-analyses show that exercise interventions during cancer treatment reduce cancer-related fatigue. However, little is known about the cost-effectiveness of such interventions. Here we aim to assess the cost-effectiveness of the 18-week physical activity during cancer treatment (PACT) intervention for patients with breast and colon cancer. The PACT trial showed beneficial effects for fatigue and physical fitness.Design Cost-effectiveness analyses with a 9-month time horizon (18 weeks of intervention and 18 weeks of follow-up) within the randomised controlled multicentre PACT study.Setting Outpatient clinics of 7 hospitals in the Netherlands (1 academic and 6 general hospitals)Participants 204 patients with breast cancer and 33 with colon cancer undergoing adjuvant treatment including chemotherapy.Intervention Supervised 1-hour aerobic and resistance exercise (twice per week for 18 weeks) or usual care.Main outcome measures Costs, quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio.Results For colon cancer, the cost-effectiveness analysis showed beneficial effects of the exercise intervention with incremental costs savings of €4321 and QALY improvements of 0.03. 100% of bootstrap simulations indicated that the intervention is dominant (ie, cheaper and more effective). For breast cancer, the results did not indicate that the exercise intervention was cost-effective. Incremental costs were €2912, and the incremental effect was 0.01 QALY. At a Dutch threshold value of €20 000 per QALY, the probability that the intervention is cost-effective was 2%.Conclusions Our results suggest that the 18-week exercise programme was cost-effective for colon cancer, but not for breast cancer.Trial registration number ISRCTN43801571. ER -